Table 1.

Data of vaccinated children after MIS-C and severe COVID-19 diagnosis and control cases

Variables	Cases with MIS-C (n = 29)	Cases with severe COVID-19 (n = 10)	Control cases (n = 40)
Characteristics
Age (y), median (IQR)	15 (14–17)	14 (12–16)	15 (14–16)
Male, n (%)	17 (58.6)	4 (40)	16 (40)
Duration between MIS-C/COVID-19 and vaccination (wk), median (min-max)	34 (5–64)	25.5 (12–59)	NA
COVID-19 vaccine brands, n (%)
Pfizer-Biontech	24 (82.8)	8 (80)	37 (92.5)
3 doses	2 (6.9)	0 (0)	13 (32.5)
2 doses	17 (58.6)	2 (20)	21 (52.5)
1 dose	5 (17.2)	6 (60)	3 (7.5)
Sinovac	4 (13.7)	1 (20)	2 (5.0)
2 doses	3 (10.3)	1 (20)	2 (5.0)
1 dose	1 (3.4)	0 (0)	0 (0)
2 Sinovac + 1 Pfizer-Biontech	1 (3.4)	1 (20)	1 (2.5)
Vaccine side effect, n (%)	Total (n = 64)	Total (n = 6)	Total (n = 24)
Any injection local reaction	29 (45.3)	4 (66.6)	16 (66.6)
Pain	26 (40.6)	4 (66.6)	16 (66.6)
Redness	0 (0)	0 (0)	0 (0)
Itching	0 (0)	0 (0)	0 (0)
Swelling	3 (4.7)	0 (0)	0 (0)
Any systemic reaction	35 (54.7)	1 (33.3)	8 (33.3)
Fatigue	6 (9.4)	1 (16.6)	4 (16.5)
Headache	4 (6.2)	0 (0)	2 (8.2)
Myaljia	2 (3.1)	0 (0)	0 (0)
Joint pain	4 (6.2)	0 (0)	0 (0)
Fever	6 (9.4)	1 (16.6)	2 (8.2)
Nausea	2 (3.1)	0 (0)	0 (0)
Vomiting	2 (3.1)	0 (0)	0 (0)
Loss of appetite	0 (0)	0 (0)	0 (0)
Sorethroat	1 (1.6)	0 (0)	0 (0)
Runny nose	0 (0)	0 (0)	0 (0)
Cough	1 (1.6)	0 (0)	0 (0)
Chest pain	2 (3.1)	0 (0)	0 (0)
Shortness of breath	0 (0)	0 (0)	0 (0)
Rash	0 (0)	0 (0)	0 (0)
Axiller swelling	2 (3.1)	0 (0)	0 (0)
Facial paralysis	0 (0)	0 (0)	0 (0)
Abdominal pain	3 (4.7)	0 (0)	0 (0)
Diarrhea	0 (0)	0 (0)	0 (0)
Others	0 (0)	0 (0)	0 (0)
Durations, median (min-max)
Between vaccine and side effect (d)	1 (1–30)	1 (1–2)	1 (1–1)
Length of side effect (d)	1 (1–28)	3 (1–3)	1 (1–3)
Hospitalization due to side effect, n (%)	0 (0)	0 (0)	0 (0)
Polyclinic visit due to side effect, n (%)	2 (6.8)	1 (10)	0 (0)

COVID-19 coronavirus disease 2019, MIS-C multisystem inflammatory syndrome in children, IQR interquartile range, NA not applicable